SecureWorks Corp (SecureWorks) is a global cybersecurity provider offering technology-driven solutions. It serves a range of industries including financial services, manufacturing, technology, retail, insurance, utility, and healthcare sectors.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D arm focuses on the improvement and addition of additional features to the Taegis software platform and custom-built technologies. It is also involved in designing, developing and testing of information security solutions suite. The company's research and development efforts are focused on enhancing and adding new functionality to its Taegis security platform and purpose-built technologies. It focuses on identifying adversaries and next-generation threats and develops related countermeasures that are applied to its platform to respond evolving security threats. Apart from improving its features, scalability, and functionality, the company’s R&D facility works closely with its information technology team to ensure that its software platforms are available, stable, and reliable. As of February 2024, SecureWorks owned 58 issued patents and eight pending patent applications in the US and six issued patents and 12 pending patent applications outside the US. In FY2024, the company incurred expenses of US$110.9 million on its R&D activities, which as a percentage of revenue, stood at 30.3%.